Iodine-125 Episcleral Plaque Brachytherapy for AJCC T4 Posterior Uveal Melanoma: Clinical Outcomes in 158 Patients | Zendy

Benjamin A. King | Zendy; Caroline Awh | Zendy; Brad T. Gao | Zendy; Jiajing Wang | Zendy; Mehmet Koçak | Zendy; Vanessa M. MoralesTirado | Zendy; Matthew T. Ballo | Zendy; Matthew W. Wilson | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Iodine-125 Episcleral Plaque Brachytherapy for AJCC T4 Posterior Uveal Melanoma: Clinical Outcomes in 158 Patients

Author(s) -

Benjamin A. King,

Caroline Awh,

Brad T. Gao,

Jiajing Wang,

Mehmet Koçak,

Vanessa M. MoralesTirado,

Matthew T. Ballo,

Matthew W. Wilson

Publication year - 2019

Publication title -

ocular oncology and pathology

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 0.444

H-Index - 10

eISSN - 2296-4681

pISSN - 2296-4657

DOI - 10.1159/000495249

Subject(s) - medicine , enucleation , brachytherapy , incidence (geometry) , melanoma , visual acuity , ocular melanoma , ophthalmology , surgery , cumulative incidence , radiation therapy , physics , cancer research , optics , transplantation

The aim of this study is to report the burden of ocular morbidity following iodine-125 episcleral plaque brachytherapy (EPBT) in the treatment of American Joint Committee on Cancer (AJCC) T4-staged posterior uveal melanoma (PUM).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research